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Abstract Background Vascular calciﬁcation is an orga-
nized process in which vascular smooth muscle cells
(VSMCs) are implicated primarily. The purpose of the
present study was to assess the effects of calcium antago-
nists and statins on VSMC calciﬁcation in vitro. Methods
VSMC calciﬁcation was stimulated by incubation in
growth medium supplemented with 10 mmol/l b-glycero-
phosphate, 8 mmol/l CaCl2, 10 mmol/l sodium pyruvate,
1 lmol/l insulin, 50 lg/ml ascorbic acid, and 100 nmol/l
dexamethasone (calciﬁcation medium). Calciﬁcation, pro-
liferation, and apoptosis of VSMCs were quantiﬁed.
Results Calcium deposition was stimulated dose-depen-
dently by b-glycerophosphate, CaCl2, and ascorbic acid (all
P\0.01). Addition of amlodipine (0.01–1 lmol/l) to the
calciﬁcation medium did not affect VSMC calciﬁcation.
However, atorvastatin (2–50 lmol/l) stimulated calcium
deposition dose-dependently. Combining treatments stim-
ulated calciﬁcation to a degree similar to that observed
with atorvastatin alone. Both atorvastatin and amlodipine
inhibited VSMC proliferation at the highest concentration
used. Only atorvastatin (50 lmol/l) induced considerable
apoptosis of VSMCs. Conclusion In vitro calciﬁcation of
VSMCs is not affected by amlodipine, but is stimulated by
atorvastatin at concentrations ‡10 lmol/l, which could
contribute to the plaque-stabilizing effect reported for
statins.
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Introduction
Atherosclerosis is the principal cause of coronary artery
disease, stroke, and peripheral artery disease, and is the
major cause of mortality in the Western hemisphere.
Vascular calciﬁcation is a prominent feature of athero-
sclerosis, and it is associated with an increased risk of
myocardial infarction [1]. Vascular calciﬁcation refers to
the deposition of calcium phosphate mineral, most often in
the form of hydroxyapatite, in the vessel wall. Calciﬁcation
of the vessel wall and heart valves is associated with
ageing, diabetes, and uremia [2–4].
Vascular calciﬁcation is now considered to be an
organized, regulated process comparable to bone mineral-
ization. The presence of various components associated
with bone mineralization, such as bone morphogenetic
protein, osteocalcin, osteopontin, osteoblast-like cells, and
matrix vesicles in atherosclerotic lesions supports this
concept [5–7]. Vascular cells such as vascular smooth
muscle cells (VSMCs) and pericyte-like cells play an
important role in vascular calciﬁcation [8].
The lipophilic calcium antagonist (CA) amlodipine has
been shown to restore cholesterol-induced membrane
bilayer abnormalities in VSMCs derived from the athero-
sclerotic rabbit aorta [9, 10], thereby restoring normal
calcium homeostasis. Other mechanisms, through which
CAs may affect atherosclerosis development include
inhibition of proliferation and migration of VSMCs
[11, 12], and inhibition of lipoprotein oxidation [13]. In
addition, CAs modify binding of monocytes to the
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[14]. The effects of CAs on atherosclerotic calciﬁcation
have not been widely studied, however.
Lipids may contribute to atherosclerotic calciﬁcation
[15, 16]. Recently statins have been shown to decrease the
progression of coronary artery calciﬁcation and aortic
valve calciﬁcation [17, 18]. Therapy with a combination of
a CA and a statin might be more atheroprotective than
either treatment alone [19, 20]. Combination therapy with
CA and statin was shown to improve endothelial function
and arterial compliance, to diminish LDL atherogenicity,
and to slow the progression of atherosclerosis. So far, the
effects of the combination therapy with CA and statin on
vascular calciﬁcation have not been studied extensively.
We used an in vitro model of vascular calciﬁcation by
neonatal rat VSMCs, isolated by outgrowth from aortic
explants. The purpose of this investigation was to identify
the factors, and their concentrations, that are mandatory to
induce calciﬁcation of aortic VSMCs in vitro. Since
calcium is such a major component of advanced athero-
sclerotic lesions, we furthermore studied whether the CA
amlodipine and the statin atorvastatin, alone and in com-
bination, affected calciﬁcation of aortic VSMCs in vitro.
Materials and methods
Cell culture
Vascular smooth muscle cells (VSMCs) were obtained from
segments of aortas explanted from 2-day old Wistar rats.
Aortic segments were obtained aseptically and cut open
longitudinally. The endothelium was removed by gently
rubbing the luminal side of the aortas over the surface of a
tissue culture dish (Falcon). Subsequently, the aortas were
placed, lumen side down, on the bottom of a tissue culture
ﬂask(Greiner),andallowedtoadhereforapproximately3 h.
Then tissues were immersedingrowthmediumconsisting of
Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Life
Technologies) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (Life Technologies), penicillin
(100 U/ml), and streptomycin (100 lg/ml) (both supplied
by BioWhittaker Europe). Seven days later the aortic tissues
were removed, and the VSMCs that had grown out were
detached by trypsinization. The detached cells were resus-
pended in growth medium and seeded in tissue culture ﬂasks
(Greiner), 6 or 12-well plates or on glass cover slips.
Immunocytochemistry
Subconﬂuent cultures at early passage were examined for
the presence of a-smooth muscle actin, SM myosin heavy
chain and calponin using speciﬁc antibodies (anti-SM actin
clone 1A4 (1:400), Sigma; anti-SM myosin heavy chain
(1:100), SanverTech; anti-calponin (1:10,000), Sigma).
After ﬁxation in 1% formalinin PBS on ice for 30 min, cells
were permeabilized with 0.1% Triton X-100 for 30 min,
and subsequently incubated with the primary antibody for
several hours at 4 C. Secondary antibodies were conjugated
with ﬂuorescein isothiocyanate (FITC) or Cy3 (Sigma). To
identify cell nuclei, the cells were also stained with Hoechst
33342 (10 lg/ml; Molecular Probes). Immunoﬂuorescent
images were obtained using a ﬂuorescence microscope
(Nikon Eclipse) equipped with 20·,4 0 ·, and 100· objec-
tives and a digital camera (Nikon DXM1200).
In vitro calciﬁcation of VSMCs
Calciﬁcation of VSMC cultures was induced by the method
of Shioi et al. [21] with minor modiﬁcations. When con-
ﬂuent, the incubation medium of VSMCs was switched
from growth medium to calciﬁcation medium. Calciﬁcation
medium consisted of DMEM (high glucose, 4.5 g/l) sup-
plemented with 15% FBS, penicillin (100 U/ml),
streptomycin (100 lg/ml), 8 mmol/l CaCl2, 10 mmol/l
sodium pyruvate, 1 lmol/l insulin, 50 lg/ml ascorbic acid,
10 mmol/l b-glycerophosphate, and 100 nmol/l dexa-
methasone. The medium was replaced with fresh medium
every 2–3 days. In several experiments, the concentrations
of CaCl2, ascorbic acid, b-glycerophosphate, and dexa-
methasone were varied.
In another series of experiments, calciﬁcation medium
was supplemented with amlodipine (0.01–1 lmol/l), ator-
vastatin (2–50 lmol/l), or a combination of these drugs.
The CA amlodipine was dissolved in absolute ethanol at a
concentration of 1 mmol/l. This stock solution was to be
diluted at least 1:1,000 in culture medium. Atorvastatin, an
inhibitor of HMG-CoA reductase, was dissolved in abso-
lute ethanol at a concentration of 10 mmol/l. This stock
solution was to be diluted at least 1:200 in culture medium.
Cells treated with calciﬁcation medium without added
drugs were used as controls. Appropriate amounts of sol-
vent (ethanol) were added to these controls. Addition of
ethanol at these levels did not affect cell growth. After
3 weeks of incubation, calciﬁcation was quantiﬁed.
Assessment of calcium deposition
VSMCs were decalciﬁed with 0.6 N HCl for 24 h. The
calcium contents of the supernatants were determined by
spectrophotometer using the o-cresolphthalein method
(Roche Diagnostics). After decalciﬁcation, the cells were
washed with PBS and scraped from the culture plate. The
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123protein content was measured using the BCA protein assay
(Pierce). The calcium content of the cell layer was nor-
malized to protein content.
Proliferation assay
VSMCs were seeded at a density of 5 · 10
3–2 · 10
4 cells/
well in a 96-well plate and allowed to attach overnight.
Subsequently, the standard culture medium (DMEM, 10%
FBS, antibiotics) was replaced by calciﬁcation medium
supplemented with amlodipine, atorvastatin, or a combi-
nation of both. Cell proliferation was assessed at day 4 and
day 9 using the Cell Proliferation Kit II (XTT, Roche),
which is a colorimetric assay for the non-radioactive
quantiﬁcation of cell proliferation and viability.
Detection of apoptosis
To identify apoptotic cells by assessment of condensation of
nuclear chromatin, VSMC cultures were stained with Hoe-
chst 33342 (10 lg/ml; Molecular Probes) for 10 min in the
dark. Immunoﬂuorescent images were obtained using a
ﬂuorescence microscope (Nikon Eclipse) equipped with
20x, 40x, and 100x objectives and a digital camera (Nikon
DXM1200). In 6 frames per treatment, an average of 250
nuclei per frame were assessed for the presence of apoptosis.
Statistical analysis
Resultsareexpressedasmean ± SEM.Forstatisticalanalysis,
SPSS 10.0 for Windows was used. Since the data were not
normally distributed, non-parametric tests were used for
comparisons between groups. Overall comparisons between
groups were performed with the Kruskall–Wallis test. If only
two groups were compared, Mann–Whitney rank sum tests
wereused.Pvalueslessthan0.05wereregardedassigniﬁcant.
Results
VSMCs that have been cultured from rat aortic explants for
approximately 7 days stained positive for a-smooth mus-
cle-actin, smooth muscle myosin heavy chain, and
calponin, conﬁrming the smooth muscle cell nature of these
cells (Fig. 1, online supplement). VSMCs of passage 3–6
were subsequently used in calciﬁcation experiments.
Calcium deposition and dependence of extracellular
Ca
2+ concentration
Cells were incubated with calciﬁcation medium supple-
mented with various Ca
2+ concentrations for 21 days. At
Ca
2+ concentrations £3 mmol/l, hardly any calcium depo-
sition was observed, but at Ca
2+ concentrations[3 mmol/l,
a dose-dependent increase in calcium deposition was
observed (Fig. 2A). The amount of calcium deposition was
positively correlated to calcium concentration in the culture
medium (P\0.01). We chose to continue with 8 mmol/l
of Ca
2+-ions added to the calciﬁcation medium.
Calcium deposition and dependence of extracellular
phosphate concentration
Shioi et al. have demonstrated that b-glycerophosphate
accelerates in vitro calciﬁcation of VSMCs and induces
extensive calcium deposition in a manner analogous to
in vitro mineralization by osteoblasts [21]. In our model of
Fig. 1 (A) Rat aortic VSMC
isolated by outgrowth, phase
contrast. Immunoﬂuorescent
staining of neonatal rat VSMC
incubated with (B) (and insert)
anti-smooth muscle actin Ab,
(C) anti-smooth muscle myosin
Ab, and (D) anti-calponin Ab.
Original magniﬁcation B and C
·100, D and insert ·200.
VSMC = vascular smooth
muscle cell
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123vascular calciﬁcation, the amount of calcium deposition
was positively correlated to the b-glycerophosphate con-
centration in the calciﬁcation medium (P\0.01; Fig. 2B).
Calcium deposition and dependence of extracellular
dexamethasone concentration
To determine the contribution of added dexamethasone, we
incubated the VSMCs with various concentrations of
dexamethasone (10–1,000 nmol/l). No signiﬁcant differ-
ences in calcium deposition were observed between the
cells incubated with 0, 10, 100, and 1,000 nmol/l dexa-
methasone (Fig. 3A).
Calcium deposition and dependence of extracellular
ascorbic acid concentration
To determine the contribution of ascorbic acid to calcium
deposition, we incubated VSMCs with various concentra-
tions of ascorbic acid (0, 5, 50, and 500 lg/ml). At the
highest concentration (500 lg/ml) ascorbic acid was
associated with signiﬁcantly more calcium deposition than
at all other concentrations (Fig. 3B). However, 500 lg/ml
ascorbic acid caused a considerable decrease in pH of the
culture medium. Since calcium deposition was positively
correlated with ascorbic acid concentration (P\0.01), we
decided to use 50 lg/ml ascorbic acid in future calciﬁca-
tion studies, the highest concentration of ascorbic acid that
did not cause acidiﬁcation of the medium.
Effects of amlodipine on in vitro VSMC calciﬁcation
To study the effect of the CA amlodipine on VSMC calci-
ﬁcation, VSMCs were incubated for 2–3 weeks with
calciﬁcation medium supplemented with various concentra-
tions of amlodipine (0.01–1 lmol/l). Incubation of neonatal
rat VSMCs with amlodipine had no effect on VSMC calci-
ﬁcation, at none of the concentrations tested (Fig. 4A).
Effects of atorvastatin on in vitro VSMC calciﬁcation
To study the effect of the statin atorvastatin on VSMC cal-
ciﬁcation, VSMCs were incubated for 2–3 weeks with
calciﬁcation medium supplemented with various concen-
trations of atorvastatin (2–50 lmol/l). Atorvastatin
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Fig. 2 (A) Dose-dependent effects ofCaCl2 oncalciﬁcationofneonatal
rat VSMCs. (B) Dose-dependent effects of b-glycerophosphate on
calciﬁcation of neonatal rat VSMCs. VSMCs were treated for 21 days
with calciﬁcation medium containing varying concentrations of Ca
2+
ions or b-glycerophosphate.Controlcultures (=con) were incubated with
DMEM, 10% FBS, and antibiotics. Calcium deposition was quantiﬁed
by o-cresolphthalein method. The data are presented as mean ± SEM
(n = 3–9). *P\0.05 vs. control cultures. uP\0.05 vs. 2 and 3 mM
calcium in culture medium. #P\0.05 vs. all other treatments
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Fig. 3 (A) Dose-dependent effects of dexamethasone on calciﬁcation
of neonatal rat VSMCs. (B) Dose-dependent effects of ascorbic acid
on calciﬁcation of neonatal rat VSMCs. VSMCs were treated for
21 days with calciﬁcation medium containing varying amounts of
dexamethasone or ascorbic acid. Calcium deposition was quantiﬁed
by o-cresolphthalein method. The data are presented as mean ± SEM
(n = 6–12). #P\0.05 vs. all other treatments. uP\0.05 vs. 0 and
5 lg/ml ascorbic acid
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123increased VSMC calciﬁcation dose-dependently (Fig. 4B).
At a concentration of 2 lmol/l atorvastatin, calcium depo-
sition was increased by 30% (P = 0.04) when compared to
VSMCs incubated with atorvastatin-free calciﬁcation med-
ium. At concentrations of 10 and 50 lmol/l atorvastatin,
calcium deposition was increased 2.3-fold and 6.1-fold,
respectively (P\0.001) when compared to VSMCs incu-
bated with atorvastatin-free calciﬁcation medium.
Effect of a combination of CA and statin on in vitro
VSMC calciﬁcation
To study the effect of combining amlodipine and atorva-
statin treatment on VSMC calciﬁcation, VSMCs were
incubated for 2–3 weeks with calciﬁcation medium sup-
plemented with 0.1 lmol/l amlodipine, 10 lmol/l
atorvastatin, or a combination of these drugs in the same
concentrations. Incubation of VSMCs with 0.1 lmol/l
amlodipine had no effect on VSMC calciﬁcation. Incuba-
tion of VSMCs with 10 lmol/l atorvastatin resulted in a
2.2-fold increased calcium deposition when compared to
control cultures treated with calciﬁcation medium only
(Fig. 4C) (P\0.001). Treatment with a combination of
amlodipine and atorvastatin also resulted in a 2.2-fold
increased calcium deposition when compared to control
cultures treated with calciﬁcation medium only
(P = 0.026). The combination therapy resulted in signiﬁ-
cantly more calcium deposition than treatment with
amlodipine alone (P = 0.003), and as much calcium depo-
sition compared to treatment with atorvastatin alone (n.s.).
Effects of amlodipine, atorvastatin, and their
combination on VSMC proliferation
VSMC proliferation was assessed at day 4 and day 9. After
4 days of incubation in calciﬁcation medium supplemented
with amlodipine (1 lmol/l), VSMC proliferation was
decreased by 21% (P\0.001) as compared to prolifera-
tion of VSMCs cultured in amlodipine-free calciﬁcation
medium (Fig. 6A, online supplement). After 9 days of
incubation, VSMC proliferation had increased by 14%
(P\0.05) when treated with 0.01 lmol/l amlodipine, but
at an amlodipine concentration of 1 lmol/l, VSMC pro-
liferation had decreased by 26% (P\0.01) as compared to
proliferation of VSMCs cultured in amlodipine-free calci-
ﬁcation medium (Fig. 5A). Atorvastatin, at a concentration
of 50 lmol/l, decreased VSMC proliferation by 50%
(P\0.001; Fig. 5B). Treatment of VSMCs with the
combination of 0.1 lmol/l amlodipine and 10 lmol/l
atorvastatin did not result in signiﬁcant changes in cell
proliferation compared to VSMCs incubated in the absence
of these drugs.
Effects of amlodipine, atorvastatin, and their
combination on VSMC apoptosis
VSMCs incubated in calciﬁcation medium only and
VSMCs incubated with amlodipine (0.01–1 lmol/l) or
atorvastatin (2 and 10 lmol/l) in calciﬁcation medium for
72 h hardly contained any apoptotic nuclei. Amlodipine at
the highest concentration tested (1 lmol/l), caused apop-
tosis of on average 0.05% of the cells (n.s. compared to
control). At the highest concentration of atorvastatin
(50 lmol/l), however, 5.6% of the nuclei were apoptotic
(P\0.05 vs. control, 2 and 10 lmol/l atorvastatin; Fig. 6).
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Fig. 4 (A) Dose-dependent effects of amlodipine on calciﬁcation of
neonatal rat VSMCs. (B) Dose-dependent effects of atorvastatin on
calciﬁcation of neonatal rat VSMCs. (C) Effects of amlodipine,
atorvastatin and a combination of both treatments on neonatal rat
VSMC calciﬁcation. VSMCs were treated for 21 days with calciﬁcation
mediumcontainingvaryingconcentrationsofatorvastatinoramlodipine,
a combination of both, or none of them (control). Calcium deposition
was quantiﬁed by o-cresolphthalein method. The data are presented as
mean ± SEM (n =1 5 ) .* P\0.05 when compared to untreated control
cultures. #P\0.05 when compared to all other treatments
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123VSMCs treated with the combination of 0.1 lmol/l
amlodipine and 10 lmol/l atorvastatin for 72 h had a
number of apoptotic nuclei that did not signiﬁcantly differ
from those observed in 10 lmol/l atorvastatin only,
0.1 lmol/l amlodipine only, and VSMCs incubated in
calciﬁcation medium in the absence of these drugs.
Discussion
In an in vitro model of vascular calciﬁcation of rat aortic
VSMCs, calcium deposition was dependent upon the
extracellular concentration of organic phosphate
(P\0.01), calcium ions (P\0.01), and ascorbic acid
(P\0.01). While studying the effect of the CA amlodip-
ine and the statin atorvastatin, alone and in combination, on
calciﬁcation, we found that, at none of the concentrations
tested (0.01–1 lmol/l) did amlodipine have any effect on
VSMC calciﬁcation in this model, nor on development of
apoptosis. In contrast, atorvastatin stimulated VSMC cal-
ciﬁcation at a concentration of ‡10 lmol/l (P\0.05), and
50 lmol/l inhibited VSMC proliferation and induced
apoptosis (P\0.05).
VSMCs retain remarkable plasticity, even in adult ani-
mals. VSMCs can undergo rapid and reversible changes in
its phenotype in response to changes in local environmental
conditions [22]. Due to production of a variety of cytokines
by subendothelial macrophages, proliferation, and migra-
tion of VSMCs to the intimal layer can occur, thereby
contributing to the process of intimal thickening and
atherosclerosis.
Neonatal VSMCs resemble VSMCs in atherosclerotic
plaque, since they retain the proliferative phenotype.
Neonatal aortic explants exhibit rapid outgrowth of
VSMCs, and we chose to use these cells to develop a model
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Fig. 5 Effect of amlodipine and atorvastatin on VSMC proliferation.
VSMC proliferation was assessed at day 4 and day 9 using the Cell
Proliferation Kit II (XTT)(Roche). VSMC proliferation is depicted as
percentage relative to untreated cells (=100%) (A) Effect of
amlodipine. (B) Effect of atorvastatin. #P\0.05 vs. control cultures.
*P\0.05 vs. control cultures
Fig. 6 VSMCs were treated
with 1 lmol/l amlodipine (A, B)
or 50 lmol/l atorvastatin (C, D)
for 72 h. Nuclei were visualized
with Hoechst 33342. Apoptotic
nuclei are circled in panel C and
indicated with arrows in panel
D. Microscopy: magniﬁcation A
and C ·100, B and D ·400
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123of vascular calciﬁcation. VSMCs were shown to migrate
from the aortic explant within several days, and were
identiﬁed as VSMCs by immunohistochemistry [8].
Dialysis patients have accelerated atherosclerosis, with
extensive calciﬁcation of both the intima and the media
[23]. Hyperphosphatemia has been implicated in this pro-
cess [24]. Inorganic phosphate (Pi) levels have previously
been shown to regulate human aortic smooth muscle cell
(HSMC) culture mineralization in vitro [25, 26]. In the
present study, the amount of calcium deposition in neonatal
rat VSMCs correlated positively to the b-glycerophosphate
concentration in the calciﬁcation medium.
In the present study, the amount of calcium deposition in
rat aortic VSMCs correlated to the calcium concentration
in the calciﬁcation medium. This observation was not a
result of passive calcium deposition, since incubation of
VSMCs with normal growth medium supplemented with
8 mmol/l CaCl2 (ﬁnal concentration) did not result in cal-
cium deposition by these cells.
Shioi et al. [21] have previously demonstrated that
culturing bovine VSMCs in the presence of b-glycero-
phosphate, ascorbic acid, and insulin can induce diffuse
calciﬁcation in a manner analogous to in vitro minerali-
zation of osteoblasts. The present study also showed that
b-glycerophosphate is crucial for the induction of calciﬁ-
cation in rat aortic VSMCs. Ascorbic acid augments this
process. Dexamethasone was demonstrated to be less vital
in this model of aortic VSMC calciﬁcation.
Statins possess potent lipid-lowering effects. Besides,
statins exert pleiotropic effects on vascular wall cells,
which include improvement of endothelial function, sta-
bilization of the atherosclerotic plaque, and suppression of
inﬂammation [27, 28]. Although several studies have failed
to demonstrate an effect of statins on the progression of
calciﬁc aortic stenosis [29, 30], statins have also been
shown to decrease the progression of coronary artery cal-
ciﬁcation and aortic valve calciﬁcation [17, 18, 31, 32].
Accordingly, Kizu et al. have demonstrated that statins
inhibit calciﬁcation in an in vitro model of inﬂammatory
vascular calciﬁcation [33]. Using interferon-c,1 a, 25-
dihydroxyvitamin D3, tumor necrosis factor-a, and onco-
statin M to induce calciﬁcation in human VSMCs, it was
demonstrated that cerivastatin and atorvastatin inhibited
calciﬁcation dose-dependently. However, one should real-
ize that this model differs from the model we have used in
the present study. Whereas Kizu et al. used inﬂammatory
mediators to induce calciﬁcation of the VSMCs, we used
increased levels of CaCl2 and organic phosphate in the
culture medium to promote calciﬁcation. Statins are known
to have anti-inﬂammatory effects, and therefore, their
inhibitory effect on calciﬁcation induced by inﬂammatory
mediators is to be expected. In addition, low doses of
statins have also been shown to protect human aortic
VSMCs from inorganic phosphate-induced calciﬁcation
[34].
In contrast to the aforementioned studies, the present
study showed a dose-dependent stimulatory effect of
atorvastatin (10 and 50 lmol/l) on calciﬁcation of VSMCs
incubated in calciﬁcation medium. However, the dose of
atorvastatin used in the present study was much higher than
in the study described by Son et al. (500x higher at the
highest dose) [34], and most likely explains the discrep-
ancy between the results obtained by Son et al. and the
results of the present study.
Reynolds et al. [35] have demonstrated that human
VSMCs undergo vesicle-mediated calciﬁcation in response
to changes in calcium and phosphate concentrations in the
culture medium. Elevated calcium and phosphate concen-
trations resulted in increased release of vesicles and
stimulation of apoptosis. Calciﬁcation was initiated by
release of membrane-bound matrix vesicles from living
cells and also by apoptotic bodies from dying cells.
Vesicles released by VSMCs after prolonged exposure to
calcium and phosphate contained preformed basic calcium
phosphate, and calciﬁed extensively. The present study
conﬁrms that statins stimulate apoptosis of VSMCs.
Apoptotic bodies can calcify extensively [36], so a likely
mechanism of induction of calciﬁcation by atorvastatin is
through induction of apoptosis. Indeed, atorvastatin stim-
ulated both apoptosis and calciﬁcation in our model.
Myocardial infarction and unstable angina usually arise
fromthedisruptionofmildlystenosedatheroscleroticlesions.
Such vulnerable plaques typically contain a large amount of
lipid and have a preponderance of inﬂammatory cells at the
shoulders of the plaque and a thin ﬁbrous cap. Calcium is
found infrequently in the culprit lesion of ruptured plaque.
Thus, plaque vulnerability is not associated with size, but
with composition. Beckman et al. [37] presented the concept
‘‘that calcium is not a critical substrate for plaque disruption
and is, in fact, associated with more stable plaques.’’ There-
fore, statin-induced alterations in the plaque’s composition
from lipid to ﬁbrous tissue without or with calciﬁcation
would decrease the plaque’s vulnerability to rupture, thereby
decreasing the risk of acute coronary syndromes.
Prolonged intensive lipid-lowering has been demon-
strated to increase calcium content of plaques as assessed
by MRI in vivo, and lowered plaque lipid content at about
the same extent, without a pronounced effect on plaque
size [38]. Since atherosclerotic plaque composition plays
an important role in plaque stability, with lipids destabi-
lizing the plaque and calciﬁcation stabilizing the plaque,
the effect of statins on plaque composition may be
favorable. In addition to lipid-lowering and calciﬁcation-
inducing effects, we observed that statins have an
anti-proliferative effect on VSMCs. Less proliferation of
VSMCs may destabilize the plaque. However, this only
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123occurred at high doses of atorvastatin, whereas calciﬁcation
induction occurred at lower dose of atorvastatin.
Although several in vitro and in vivo studies have
demonstrated that combining CA and statin therapy might
be more atheroprotective than either treatment alone
[19, 20, 39], the present study found no difference between
the combination of amlodipine and atorvastatin therapy,
and atorvastatin therapy alone on VSMC calciﬁcation.
In conclusion, extracellular b-glycerophosphate and
CaCl2 concentrations are important determinants of in
vitro calciﬁcation of rat aortic VSMCs. Ascorbic acid
stimulates this process. Dexamethasone was demonstrated
to be less vital in this model of VSMC calciﬁcation. In
vitro calciﬁcation of rat aortic VSMCs is not affected by
amlodipine treatment, but is stimulated by atorvastatin
treatment. As high concentrations of atorvastatin have a
pro-apoptotic effect, the pro-calciﬁcation effect of atorva-
statin may be explained by the production of apoptotic
bodies that act as foci for calcium deposition. The latter
ﬁnding may explain the plaque-stabilizing effect reported
for statins.
References
1. Detrano RC, Wong ND, Doherty TM et al (1997) Prognostic
signiﬁcance of coronary calciﬁc deposits in asymptomatic high-
risk subjects. Am J Med 102:344–349
2. Devries S, Wolfkiel C, Fusman B et al (1995) Inﬂuence of age
and gender on the presence of coronary calcium detected by
ultrafast computed tomography. J Am Coll Cardiol 25:76–82
3. Goodman WG, Goldin J, Kuizon BD et al (2000) Coronary-
artery calciﬁcation in young adults with end-stage renal disease
who are undergoing dialysis. N Engl J Med 342:1478–1483
4. Wagenknecht LE, Bowden DW, Carr JJ et al (2001) Familial
aggregation of coronary artery calcium in families with type 2
diabetes. Diabetes 50:861–866
5. Anderson HC (1983) Calciﬁc diseases. A concept. Arch Pathol
Lab Med 107:341–348
6. Bostrom K, Watson KE, Horn S et al (1993) Bone morphogenetic
protein expression in human atherosclerotic lesions. J Clin Invest
91:1800–1809
7. Mohler ER III, Gannon F, Reynolds C et al (2001) Bone for-
mation and inﬂammation in cardiac valves. Circulation 103:
1522–1528
8. Trion A, van der Laarse A (2004) Vascular smooth muscle cells
and calciﬁcation in atherosclerosis. Am Heart J 147:808–814
9. Nayler WG (1999) Review of preclinical data of calcium channel
blockers and atherosclerosis. J Cardiovasc Pharmacol 33(Suppl
2):S7–S11
10. Tulenko TN, Sumner AE, Chen M et al (2001) The smooth
muscle cell membrane during atherogenesis: a potential target for
amlodipine in atheroprotection. Am Heart J 141:S1–11
11. Betz E, Weiss HD, Heinle H et al (1991) Calcium antagonists
and atherosclerosis. J Cardiovasc Pharmacol 18(Suppl 10):
S71–S75
12. Waters D, Lesperance J, Francetich M et al (1990) A controlled
clinical trial to assess the effect of a calcium channel blocker
on the progression of coronary atherosclerosis. Circulation
82:1940–1953
13. Mak IT, Boehme P, Weglicki WB (1992) Antioxidant effects of
calcium channel blockers against free radical injury in endothelial
cells. Correlation of protection with preservation of glutathione
levels. Circ Res 70:1099–1103
14. Eickelberg O, Roth M, Block LH (1997) Effects of amlodipine on
gene expression and extracellular matrix formation in human
vascular smooth muscle cells and ﬁbroblasts: implications for
vascular protection. Int J Cardiol 62(Suppl 2):S31–S37
15. Parhami F, Morrow AD, Balucan J et al (1997) Lipid oxidation
products have opposite effects on calcifying vascular cell and
bone cell differentiation. A possible explanation for the paradox
of arterial calciﬁcation in osteoporotic patients. Arterioscler
Thromb Vasc Biol 17:680–687
16. Pohle K, Maeffert R, Ropers D et al (2001) Progression of aortic
valve calciﬁcation. Association with coronary atherosclerosis and
cardiovascular risk factors. Circulation 104:1927–1932
17. Achenbach S, Ropers D, Pohle K et al (2002) Inﬂuence of lipid-
lowering therapy on the progression of coronary artery calciﬁ-
cation: a prospective evaluation. Circulation 106:1077–1082
18. Shavelle DM, Takasu J, Budoff MJ et al (2002) HMG CoA
reductase inhibitor (statin) and aortic valve calcium. Lancet
359:1125–1126
19. Jukema JW, Zwinderman AH, van Boven AJ et al (1996) Evi-
dence for a synergistic effect of calcium channel blockers with
lipid-lowering therapy in retarding progression of coronary ath-
erosclerosis in symptomatic patients with normal to moderately
raised cholesterol levels. The REGRESS Study Group. Arte-
rioscler Thromb Vasc Biol 16:425–430
20. Leibovitz E, Beniashvili M, Zimlichman R et al (2003) Treat-
ment with amlodipine and atorvastatin have additive effect in
improvement of arterial compliance in hypertensive hyperlipi-
demic patients. Am J Hypertens 16:715–718
21. Shioi A, Nishizawa Y, Jono S et al (1995) Beta-glycerophosphate
accelerates calciﬁcation in cultured bovine vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol 15:2003–2009
22. Schwartz SM, Campbell GR, Campbell JH (1986) Replication of
smooth muscle cells in vascular disease. Circ Res 58:427–444
23. Locatelli F, Cannata-Andia JB, Drueke TB et al (2002) Man-
agement of disturbances of calcium and phosphate metabolism in
chronic renal insufﬁciency, with emphasis on the control of
hyperphosphataemia. Nephrol Dial Transplant 17:723–731
24. Shioi A, Taniwaki H, Jono S et al (2001) Monckeberg’s medial
sclerosis and inorganic phosphate in uremia. Am J Kidney Dis
38:S47–S49
25. Giachelli CM, Jono S, Shioi A et al (2001) Vascular calciﬁcation
and inorganic phosphate. Am J Kidney Dis 38:S34–S37
26. Jono S, McKee MD, Murry CE et al (2000) Phosphate regulation
of vascular smooth muscle cell calciﬁcation. Circ Res 87:E10–
E17
27. Kwak BR, Mulhaupt F, Mach F (2003) Atherosclerosis: anti-
inﬂammatory and immunomodulatory activities of statins.
Autoimmun Rev 2:332–338
28. Takemoto M, Liao JK (2001) Pleiotropic effects of 3-hydroxy-3-
methylglutaryl Coenzyme A reductase inhibitors. Arterioscler
Thromb Vasc Biol 21:1712–1719
29. Wanner C, Krane V, Marz W et al (2006) Atorvastatin in patients
with type 2 diabetes mellitus undergoing hemodialysis. N Engl J
Med 353:238–248
30. Cowell SJ, Newby DE, Prescott RJ et al (2005) A randomized
trial of intensive lipid-lowering therapy in calciﬁc aortic stenosis.
N Engl J Med 352:2389–2397
31. Novaro GM, Tiong IY, Pearce GL et al (2001) Effect of
hydroxymethylglutaryl coenzyme A reductase inhibitors on
32 Mol Cell Biochem (2008) 308:25–33
123the progression of calciﬁc aortic stenosis. Circulation 104:
2205–2209
32. Callister TQ, Raggi P, Cooil B et al (1998) Effect of HMG-CoA
reductase inhibitors on coronary artery disease as assessed
by electron-beam computed tomography. N Engl J Med 339:
1972–1978
33. Kizu A, Shioi A, Jono S et al (2004) Statins inhibit in vitro
calciﬁcation of human vascular smooth muscle cells induced by
inﬂammatory mediators. J Cell Biochem 93:1011–1019
34. Son B, Kozaki K, Iijima K et al (2006) Statins protect human
aortic smooth muscle cells from inorganic phosphate-induced
calciﬁcation by restoring Gas6–Axl survival pathway. Circ Res
98:1024–1031
35. Reynolds JL, Joannides AJ, Skepper JN et al (2004) Human
vascular smooth muscle cells undergo vesicle-mediated calciﬁ-
cation in response to changes in extracellular calcium and
phosphate concentrations: a potential mechanism for accelerated
vascular calciﬁcation. J Am Soc Nephrol 15:2857–2867
36. Proudfoot D, Skepper JN, Hegyi L et al (2000) Apoptosis reg-
ulates human vascular calciﬁcation in vitro: evidence for
initiation of vascular calciﬁcation by apoptotic bodies. Circ Res
87:1055–1062
37. Beckman JA, Ganz J, Craeger MA et al (2001) Relationship of
clinical presentation and calciﬁcation of culprit coronary artery
stenoses. Arterioscler Thromb Vasc Biol 21:1618–1622
38. Zhao XQ, Yuan C, Hatsukami TS et al (2001) Effects of pro-
longed intensive lipid-lowering therapy on the characteristics of
carotid atherosclerotic plaques in vivo by MRI: a case-control
study. Arterioscler Thromb Vasc Biol 21:1623–1629
39. Anon (2003) Effect of nifedipine and cerivastatin on coronary
endothelial function in patients with coronary artery disease: the
ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On
Recovery of coronary Endothelial function). Circulation
107:422–428
Mol Cell Biochem (2008) 308:25–33 33
123